Search

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.

inauguration_biopharmaceutical_production_facility_vienna

The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

Supporting Rabies Free Pakistan Indus Hospital

Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.

Rabies prevention local action partnering organizations

Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.

cystic fibrosis phase II trial

The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

Vicadrostat (BI 690517) + empagliflozin

Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC

Boehringer Ingelheim advances SIRP immune-oncology program

Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Survodutide (BI 456906): GLP1/GCGR agonist | MASH

FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program

Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC

Survodutide (BI 456906): GLP1/GCGR agonist | obesity

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.

World Rabies Day: BI fights rabies misconceptions

Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.

Geographic Atrophy treatment to move to Phase II

Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results

Over 100 billion birds vaccinated with VAXXITEK

Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.

Big Little Things in cancer: small things, big impacts

Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.

All hands-on deck to fight the ‘zombie’ rabies virus

We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.

Phase 1 start for novel triple agonist obesity treatment

Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment

International Postdocs realize their potential in Biberach

Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

BI Access to Healthcare Strategy_Availability

inauguration_biopharmaceutical_production_facility_vienna

Phase II trial results in people living with obesity or overweight

Supporting Rabies Free Pakistan Indus Hospital

Rabies prevention local action partnering organizations

cystic fibrosis phase II trial

BTD for GlyT1 in Schizophrenia

Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met

Vicadrostat (BI 690517) + empagliflozin

Vicadrostat (BI 690517) + empagliflozin

Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC

Boehringer Ingelheim advances SIRP immune-oncology program

Survodutide (BI 456906): GLP1/GCGR agonist | MASH

FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs

Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC

Survodutide (BI 456906): GLP1/GCGR agonist | obesity

Digital solutions save lives

clinical_collaboration_with_Mirati

World Rabies Day: BI fights rabies misconceptions

Geographic Atrophy treatment to move to Phase II

Over 100 billion birds vaccinated with VAXXITEK

Big Little Things in cancer: small things, big impacts

All hands-on deck to fight the ‘zombie’ rabies virus

Phase 1 start for novel triple agonist obesity treatment

International Postdocs realize their potential in Biberach